A detailed history of Vanguard Group Inc transactions in Aura Biosciences, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,805,434 shares of AURA stock, worth $18.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,805,434
Previous 1,767,410 2.15%
Holding current value
$18.7 Million
Previous $13.4 Million 20.4%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$6.9 - $10.36 $262,365 - $393,928
38,024 Added 2.15%
1,805,434 $16.1 Million
Q2 2024

Aug 13, 2024

BUY
$6.81 - $7.89 $544,800 - $631,200
80,000 Added 4.74%
1,767,410 $13.4 Million
Q1 2024

May 10, 2024

SELL
$7.09 - $9.24 $305,018 - $397,514
-43,021 Reduced 2.49%
1,687,410 $13.2 Million
Q4 2023

Feb 14, 2024

BUY
$7.02 - $11.98 $4.91 Million - $8.38 Million
699,337 Added 67.82%
1,730,431 $15.3 Million
Q3 2023

Nov 14, 2023

BUY
$8.97 - $12.38 $26,210 - $36,174
2,922 Added 0.28%
1,031,094 $9.25 Million
Q2 2023

Aug 14, 2023

SELL
$8.51 - $13.33 $173,731 - $272,131
-20,415 Reduced 1.95%
1,028,172 $12.7 Million
Q1 2023

May 15, 2023

BUY
$8.88 - $12.11 $1.64 Million - $2.24 Million
185,007 Added 21.42%
1,048,587 $9.73 Million
Q4 2022

Feb 10, 2023

BUY
$9.86 - $14.59 $2.54 Million - $3.76 Million
257,696 Added 42.53%
863,580 $9.07 Million
Q3 2022

Nov 14, 2022

BUY
$13.1 - $20.34 $2.24 Million - $3.47 Million
170,709 Added 39.23%
605,884 $11 Million
Q2 2022

Aug 12, 2022

BUY
$12.37 - $21.86 $2.55 Million - $4.52 Million
206,542 Added 90.34%
435,175 $6.17 Million
Q1 2022

May 13, 2022

BUY
$15.94 - $23.34 $37,857 - $55,432
2,375 Added 1.05%
228,633 $5.03 Million
Q4 2021

Feb 14, 2022

BUY
$14.76 - $24.89 $3.34 Million - $5.63 Million
226,258 New
226,258 $3.84 Million

Others Institutions Holding AURA

About Aura Biosciences, Inc.


  • Ticker AURA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,273,600
  • Market Cap $302M
  • Description
  • Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develop...
More about AURA
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.